Teva Pharmaceutical Industries Limited Company Profile (NYSE:TEVA)

About Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Teva Pharmaceutical Industries Limited logoTeva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women's health and selected other areas.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NYSE:TEVA
  • CUSIP: N/A
  • Web: www.tevapharm.com
Capitalization:
  • Market Cap: $15.14 billion
  • Outstanding Shares: 1,016,000,000
Average Prices:
  • 50 Day Moving Avg: $16.57
  • 200 Day Moving Avg: $25.51
  • 52 Week Range: $14.30 - $44.42
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 3.95
  • P/E Growth: -0.51
Sales & Book Value:
  • Annual Revenue: $23.37 billion
  • Price / Sales: 0.65
  • Book Value: $23.99 per share
  • Price / Book: 0.62
Dividend:
  • Annual Dividend: $0.94
  • Dividend Yield: 7.4%
Profitability:
  • EBITDA: $7.42 billion
  • Net Margins: -25.18%
  • Return on Equity: 15.96%
  • Return on Assets: 5.31%
Debt:
  • Debt-to-Equity Ratio: 1.30%
  • Current Ratio: 0.94%
  • Quick Ratio: 0.61%
Misc:
  • Average Volume: 24.26 million shs.
  • Beta: 0.57
  • Short Ratio: 4.71
 

Frequently Asked Questions for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

What is Teva Pharmaceutical Industries Limited's stock symbol?

Teva Pharmaceutical Industries Limited trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

How often does Teva Pharmaceutical Industries Limited pay dividends? What is the dividend yield for Teva Pharmaceutical Industries Limited?

Teva Pharmaceutical Industries Limited declared a quarterly dividend on Monday, August 7th. Stockholders of record on Tuesday, August 29th will be paid a dividend of $0.085 per share on Thursday, September 14th. This represents a $0.34 annualized dividend and a dividend yield of 2.28%. The ex-dividend date is Friday, August 25th. View Teva Pharmaceutical Industries Limited's Dividend History.

How were Teva Pharmaceutical Industries Limited's earnings last quarter?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced its quarterly earnings results on Thursday, August, 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.06 by $0.07. The business had revenue of $5.69 billion for the quarter, compared to analysts' expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. Teva Pharmaceutical Industries Limited's quarterly revenue was up 12.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.25 EPS. View Teva Pharmaceutical Industries Limited's Earnings History.

When will Teva Pharmaceutical Industries Limited make its next earnings announcement?

Teva Pharmaceutical Industries Limited is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Teva Pharmaceutical Industries Limited.

What guidance has Teva Pharmaceutical Industries Limited issued on next quarter's earnings?

Teva Pharmaceutical Industries Limited updated its FY17 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of $4.30-4.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.73. The company issued revenue guidance of $22.8-23.2 billion, compared to the consensus revenue estimate of $23.43 billion.

Where is Teva Pharmaceutical Industries Limited's stock going? Where will Teva Pharmaceutical Industries Limited's stock price be in 2017?

25 analysts have issued 1 year target prices for Teva Pharmaceutical Industries Limited's stock. Their forecasts range from $13.00 to $80.00. On average, they expect Teva Pharmaceutical Industries Limited's share price to reach $27.62 in the next year. View Analyst Ratings for Teva Pharmaceutical Industries Limited.

What are analysts saying about Teva Pharmaceutical Industries Limited stock?

Here are some recent quotes from research analysts about Teva Pharmaceutical Industries Limited stock:

  • 1. Maxim Group analysts commented, "Shares of TEVA are under pressure in the wake of the FDA’s approval of Mylan’s ANDA for generic copaxone 3x/week & 20 mg/ml QD injection. Teva has a press release estimating the impact of the two launches to its 4Q earnings of at least $0.25. Our estimates are under review but our Hold remaining remains in-effect. We had anticipated generic copaxone (3x) but not until 2018." (10/4/2017)
  • 2. According to Zacks Investment Research, "Pricing erosion in the U.S. generics business and the continued deterioration in Venezuela is hurting sales at Teva which led to a guidance and dividend cut in August. Teva is facing several other challenges in the form of generic competition for Copaxone, new competition for branded products and a high cost base and debt load. Also, Teva’s shares underperformed the generic industry this year so far. Nonetheless, Teva is progressing with its branded/generics drugs pipeline and is looking to strengthen its biosimilar pipeline. The Actavis Generics acquisition is contributing to growth of the Generics unit. Meanwhile, Teva is focusing on cost cutting and divestments to boost growth. However, a clear path to growth is not visible. Estimates have declined ahead of the company’s Q3 earnings release. The company also has a negative record of earnings surprises in recent quarters." (10/4/2017)
  • 3. Jefferies Group LLC analysts commented, "MDCO announced early stoppage of the Ph 3 TANGO-2 trial for Vabomere (Carbavance) based on an interim analysis which showed a superior benefit-risk compared to best available therapy in serious infections due to CRE. We are impressed by DSMB stoppage of a trial with less than half of patients enrolled (72 out of the 150 target) suggesting a dramatic clinical benefit vs. standard of care. We believe today’s news provides a favorable setup for the August 21 (our estimate) PDUFA for Vabomere in cUTI. We continue to see Vabomere as a potential source of optionality for MDCO should management decide to launch this important new antibiotic on their own or in conjunction with a partner." (7/25/2017)
  • 4. Royal Bank Of Canada analysts commented, "TEVA reported 4Q above Street expectations and reaffirmed 2017 guidance with some further color around the year. The bull case in TEVA lacks conviction and change is needed. We look to CEO search/ strategic review, potential for break-up, and potential upside from generic Copaxone surprise as opportunity but near-term confidence remains low. No change to PT but EPS moves lower to reflect greater competitive pressures." (2/14/2017)

Are investors shorting Teva Pharmaceutical Industries Limited?

Teva Pharmaceutical Industries Limited saw a increase in short interest in September. As of September 29th, there was short interest totalling 44,659,599 shares, an increase of 5.7% from the September 15th total of 42,266,528 shares. Based on an average daily volume of 16,022,193 shares, the short-interest ratio is currently 2.8 days. Approximately 4.4% of the company's stock are short sold.

Who are some of Teva Pharmaceutical Industries Limited's key competitors?

Who are Teva Pharmaceutical Industries Limited's key executives?

Teva Pharmaceutical Industries Limited's management team includes the folowing people:

  • Sol J. Barer Ph.D., Chairman of the Board
  • Yitzhak Peterburg, Interim President and Chief Executive Officer
  • Kaare Schultz, President, Chief Executive Officer
  • Eyal Desheh, Group Executive Vice President, Chief Financial Officer
  • Dipankar Bhattacharjee, President and Chief Executive Officer-Global Generic Medicines Group
  • Carlo de Notaristefani, President and Chief Executive Officer-Global Operations
  • Robert Koremans, President, Chief Executive Officer - Global Specialty Medicines
  • Iris Beck-Codner, Group Executive Vice President - Corporate Marketing & Communication
  • Hafrun Fridriksdottir, Executive Vice President, President of Global Generics R&D
  • Mark Sabag, Group Executive Vice President-Human Resources

Who owns Teva Pharmaceutical Industries Limited stock?

Teva Pharmaceutical Industries Limited's stock is owned by many different of institutional and retail investors. Top institutional investors include PGGM Investments (0.15%), APG Asset Management N.V. (0.02%), Exane Derivatives (0.00%), Guardian Investment Management (0.00%) and Private Asset Management Inc. (0.00%). View Institutional Ownership Trends for Teva Pharmaceutical Industries Limited.

Who sold Teva Pharmaceutical Industries Limited stock? Who is selling Teva Pharmaceutical Industries Limited stock?

Teva Pharmaceutical Industries Limited's stock was sold by a variety of institutional investors in the last quarter, including Private Asset Management Inc.. View Insider Buying and Selling for Teva Pharmaceutical Industries Limited.

Who bought Teva Pharmaceutical Industries Limited stock? Who is buying Teva Pharmaceutical Industries Limited stock?

Teva Pharmaceutical Industries Limited's stock was bought by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Exane Derivatives, PGGM Investments and Guardian Investment Management. View Insider Buying and Selling for Teva Pharmaceutical Industries Limited.

How do I buy Teva Pharmaceutical Industries Limited stock?

Shares of Teva Pharmaceutical Industries Limited can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Teva Pharmaceutical Industries Limited's stock price today?

One share of Teva Pharmaceutical Industries Limited stock can currently be purchased for approximately $14.90.


MarketBeat Community Rating for Teva Pharmaceutical Industries Limited (NYSE TEVA)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  880 (Vote Outperform)
Underperform Votes:  690 (Vote Underperform)
Total Votes:  1,570
MarketBeat's community ratings are surveys of what our community members think about Teva Pharmaceutical Industries Limited and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Teva Pharmaceutical Industries Limited (NYSE:TEVA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Sell Ratings, 16 Hold Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.04)
Consensus Price Target: $27.62 (85.37% upside)
Consensus Price Target History for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Price Target History for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Analysts' Ratings History for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/20/2017Royal Bank Of CanadaSet Price TargetSell$15.00N/AView Rating Details
10/20/2017Barclays PLCSet Price TargetHold$21.00 -> $19.00N/AView Rating Details
10/19/2017Cantor FitzgeraldSet Price TargetHold$17.00N/AView Rating Details
10/6/2017Piper Jaffray CompaniesSet Price TargetHold$23.00N/AView Rating Details
10/4/2017Wells Fargo & CompanySet Price TargetHold$20.00N/AView Rating Details
10/5/2017Morgan StanleySet Price TargetUnderweight$16.00 -> $15.00N/AView Rating Details
10/4/2017Cowen and CompanyReiterated RatingMarket Perform$30.00 -> $18.00N/AView Rating Details
10/4/2017Maxim GroupReiterated RatingHoldN/AView Rating Details
10/4/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldMediumView Rating Details
10/4/2017MizuhoReiterated RatingHold$16.00MediumView Rating Details
10/4/2017BTIG ResearchReiterated RatingBuy$24.00MediumView Rating Details
9/21/2017Sanford C. BernsteinLower Price TargetMkt Perform -> Market Perform$28.00 -> $20.00LowView Rating Details
9/13/2017GabelliReiterated RatingBuyLowView Rating Details
9/12/2017Jefferies Group LLCLower Price TargetHold$21.00 -> $18.50HighView Rating Details
9/6/2017JMP SecuritiesBoost Price TargetUnderperform$13.00 -> $14.00LowView Rating Details
8/31/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$28.00 -> $21.00LowView Rating Details
8/23/2017Credit Suisse GroupDowngradeNeutral -> Underperform$25.00 -> $13.00MediumView Rating Details
8/16/2017Citigroup Inc.DowngradeBuy -> Neutral$32.00 -> $19.00MediumView Rating Details
8/9/2017Deutsche Bank AGReiterated RatingBuy$43.00 -> $28.00HighView Rating Details
8/3/2017CIBCReiterated RatingOutperform -> Market PerformHighView Rating Details
2/28/2017ArgusDowngradeBuy -> Hold$59.35 -> $31.90N/AView Rating Details
2/17/2017J P Morgan Chase & CoSet Price TargetHold$37.00N/AView Rating Details
1/31/2017Bank of America CorporationUpgradeNeutral -> BuyN/AView Rating Details
12/23/2016GuggenheimReiterated RatingBuy$80.00N/AView Rating Details
11/4/2016HSBC Holdings plcDowngradeBuy -> Hold$44.00 -> $66.00N/AView Rating Details
10/7/2016Leerink SwannSet Price TargetBuy$57.00N/AView Rating Details
9/29/2016OTR GlobalInitiated CoveragePositiveN/AView Rating Details
4/19/2016Canaccord GenuityReiterated RatingBuyN/AView Rating Details
3/2/2016NomuraReiterated RatingNeutral$73.00N/AView Rating Details
11/27/2015Berenberg BankLower Price TargetHold$72.00 -> $65.00N/AView Rating Details
(Data available from 10/22/2015 forward)

Earnings

Earnings History for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Earnings by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Earnings History by Quarter for Teva Pharmaceutical Industries Limited (NYSE TEVA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017$1.05N/AView Earnings Details
8/3/20176/30/2017$1.06$0.99$5.72 billion$5.69 billionViewListenView Earnings Details
5/11/2017Q1 17$1.06$1.06$5.69 billion$5.63 billionViewN/AView Earnings Details
2/13/2017Q416$1.36$1.38$6.26 billion$6.25 billionViewN/AView Earnings Details
11/15/2016Q316$1.29$1.31$5.71 billion$5.56 billionViewN/AView Earnings Details
8/4/2016Q216$1.20$1.25$4.86 billion$5.00 billionViewN/AView Earnings Details
5/9/2016Q116$1.17$1.20$4.78 billion$4.81 billionViewN/AView Earnings Details
2/11/2016Q415$1.29$1.28$4.83 billion$4.88 billionViewListenView Earnings Details
10/29/2015Q315$1.28$1.35$4.75 billion$4.80 billionViewListenView Earnings Details
7/30/2015Q215$1.31$1.43$4.90 billion$4.97 billionViewListenView Earnings Details
4/30/2015Q115$1.26$1.36$4.84 billion$5.00 billionViewN/AView Earnings Details
2/5/2015Q414$1.31$1.31$5.17 billion$5.17 billionViewN/AView Earnings Details
10/30/2014Q314$1.23$1.32$5.09 billion$5.06 billionViewN/AView Earnings Details
7/31/2014Q214$1.21$1.23$5.08 billion$5.00 billionViewN/AView Earnings Details
5/1/2014Q114$1.22$1.22$5.11 million$5.00 billionViewN/AView Earnings Details
2/6/2014Q413$1.26$1.42$5.19 billion$5.40 billionViewN/AView Earnings Details
10/31/2013Q313$1.26$1.27$5.00 billion$5.06 billionViewN/AView Earnings Details
8/1/2013Q213$1.20$1.20$4.94 billion$4.90 billionViewN/AView Earnings Details
5/2/2013Q113$1.10$1.12$4.85 billion$4.90 billionViewN/AView Earnings Details
2/7/2013Q412$1.33$1.32$5.26 billion$5.20 billionViewN/AView Earnings Details
11/1/2012Q312$1.25$1.28$5.08 billion$5.00 billionViewN/AView Earnings Details
8/2/2012$1.28$1.28ViewN/AView Earnings Details
5/9/2012$1.44$1.47ViewN/AView Earnings Details
2/15/2012$1.58$1.59ViewN/AView Earnings Details
11/2/2011$1.22$1.25ViewN/AView Earnings Details
7/27/2011$1.08$1.10ViewN/AView Earnings Details
5/11/2011$1.03$1.04ViewN/AView Earnings Details
2/8/2011$1.28$1.25ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Current Year EPS Consensus Estimate: $4.25 EPS
Next Year EPS Consensus Estimate: $3.77 EPS

Dividends

Current Dividend Information for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Most Recent Dividend:9/14/2017
Annual Dividend:$0.94
Dividend Yield:6.31%
Dividend Growth:2.10% (3 Year Average)
Payout Ratio:-15.36% (Trailing 12 Months of Earnings)
22.12% (Based on This Year's Estimates)
24.93% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Dividend History by Quarter for Teva Pharmaceutical Industries Limited (NYSE TEVA)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/7/2017quarterly$0.091.83%8/25/20178/29/20179/14/2017
5/11/2017quarterly$0.344.28%6/1/20176/5/20176/22/2017
2/13/2017quarterly$0.343.7%2/28/20173/2/20173/20/2017
11/15/2016quarterly$0.3412/1/201612/5/201612/20/2016
8/4/2016quarterly$0.348/18/20168/22/20169/8/2016
5/9/2016quarterly$0.345/20/20165/24/20166/7/2016
2/16/2016Quarterly$0.292/25/20162/29/20163/14/2016
10/29/2015quarterly$0.3411/13/201511/17/201512/3/2015
7/30/2015quarterly$0.348/18/20158/20/20159/3/2015
5/5/2015special$0.342.25%5/15/20155/19/20156/4/2015
2/5/2015quarterly$0.342.36%2/17/20152/19/20153/3/2015
10/31/2014special$0.322.43%11/13/201411/17/201412/2/2014
8/1/2014quarterly$0.352.61%8/19/20148/21/20149/4/2014
5/2/2014quarterly$0.352.77%5/16/20145/20/20146/2/2014
2/4/2014$0.342/20/20142/24/20143/10/2014
11/1/2013quarterly$0.333.51%11/18/201311/20/201312/2/2013
8/5/2013quarterly$0.323.34%8/16/20138/20/20139/3/2013
8/1/2013quarterly$0.328/20/20139/2/2013
5/6/2013special$0.323.28%5/16/20135/20/20136/3/2013
2/8/2013quarterly$0.313.21%2/19/20132/21/20133/7/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Latest Headlines for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Source:
Loading headlines, please wait.

Social

Chart

Teva Pharmaceutical Industries Limited (TEVA) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.